SeaStar Medical (ICU) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting is scheduled for June 17, 2026, and will be held virtually, allowing shareholders to vote and submit questions online.
Shareholders of record as of April 24, 2026, are entitled to vote on key proposals, including director election, equity plan amendment, auditor ratification, and potential adjournment.
The proxy materials include the annual report, voting instructions, and details on how to participate in the meeting.
Voting matters and shareholder proposals
Proposal 1: Election of John Neuman as Class I director to serve until the 2029 annual meeting.
Proposal 2: Amendment and restatement of the 2022 Equity Incentive Plan to increase authorized shares from 207,046 to 896,546.
Proposal 3: Ratification of WithumSmith + Brown, PC as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proposal 4: Approval to adjourn or postpone the meeting if necessary for further solicitation of proxies.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
The board consists of five members divided into three staggered classes, with a majority deemed independent under Nasdaq standards.
Jennifer Baird serves as Chair of the Board; Eric Schlorff is CEO and director.
Committees include Audit, Compensation, and Nominating and Corporate Governance, each with independent directors.
The board has adopted a Code of Business Conduct and Ethics and an Insider Trading Policy.
The Nominating and Corporate Governance Committee considers diversity, experience, and independence in director selection.
Latest events from SeaStar Medical
- Revenue up 82% on QUELIMMUNE growth; adult trial and ICD-10-PCS codes advance, but losses persist.ICU
Q2 2026 - QUELIMMUNE SCD shows strong survival benefits in pediatric AKI and advances toward adult market approval.ICU
H.C. Wainwright 27th Annual Global Investment Conference - SCD therapy delivers improved survival in pediatric AKI and is expanding into adult markets.ICU
Investor Summit Virtual Conference - Q1 2026 revenue surged 69% to $0.5M, but going concern risk persists without new capital.ICU
Q1 2026 - Offering up to 1.66M shares for resale under a $15M equity line, targeting critical care markets.ICU
Registration filing - Offering up to 1.66M shares for resale under a $15M equity line, targeting critical care innovation.ICU
Registration filing - Revenue and margins soared as QUELIMMUNE adoption grew; SCD therapy advanced in pivotal trials.ICU
Q4 2025 - Pediatric success and adult trial progress drive expansion and regulatory momentum.ICU
Life Sciences Virtual Investor Forum - QUELIMMUNE boosts pediatric AKI survival, with adult trials and broad pipeline advancing.ICU
Biotech Showcase 2026